Search
forLearn
5 / 801 resultslearn zinc PCA
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn calcium ascorbate
learn ceramide
Research
5 / 1000+ resultsresearch The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches
Sustained-release sodium valproate is effective in treating epilepsy, with some side effects influenced by genetics.
research Valproic Acid (Depakene)
Valproic acid is effective for various seizures, but may cause temporary side effects like drowsiness and stomach issues.
research Valproic acid (Depakene). A new anticonvulsant agent
Valproic acid is an effective seizure medication with some temporary side effects.
research Development and characterization of polymeric nanoparticle-based formulation of adapalene for topical acne therapy
The new adapalene formulation using TyroSpheres is more effective and less irritating for acne treatment.
research Characterization of the in vitro, ex vivo, and in vivo Efficacy of the Antimicrobial Peptide DPK-060 Used for Topical Treatment
DPK-060 in poloxamer gel effectively treats skin infections, but nanocarriers don't enhance its efficacy.
Community Join
5 / 1000+ resultscommunity Update for PP405 - phase 2b underway
PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.
community Shiseido RCH-01
Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.
community How many years can we expect PP405 to be on the market
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
community Koshine 826 (Pyrilutamide). Any results after 5 months since it's been released?
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.